Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

Beginner's Mind

Beginner's Mind artwork

#105: Expert Insights on Biophysics and the Future of Drug Discovery: An Interview with Dr. Thomas Schubert of 2bind

Jan 23, 202336 minAudio

Are you ready for the grand finale of our Year in Review Recording? The final episode of 2022 is here, and it's one for the books! We've explored the cutting-edge innovations and technologies shaping the future of the biotech industry with some of the most brilliant minds in the field. From Kurt Höller of EIT Health, to Albert Missbichler from Fianostics, Caroline Heil from the new meat company, Mauricio Agudelo and Lina Toro from Bialtec, Kimberly Cornfield from the UCL, Collin Ewald from ETH Zurich, and Guido Gualdoni from G.ST Antiviral, we've had some truly enlightening conversations. But we saved the best for last! Get ready for an exclusive interview with Dr. Thomas Schubert, CEO of 2bind, a provider of biophysical outsourcing solutions that is revolutionizing the way we study molecular interactions and protein stability. Don't miss out on this one-of-a-kind episode. Tune in now! This cutting-edge biotech company is revolutionizing how we study molecular interactions and protein stability. They're doing it with a track record of over 1400 successfully completed tasks in research projects with over 350 customers in the last 11 years. In this episode, you'll get an inside look at the driving force behind 2bind and the expert knowledge that sets them apart in the biophysics field. From breakthrough moments to industry trends, you'll gain a deeper understanding of the future of biotech and the role that companies like 2bind will play in shaping it. But that's not all! You'll also hear from Dr. Schubert about the company's partnerships with leading device producers and how they navigate the digital world to stay ahead of the curve. Plus, you'll get insight into the supply chain challenges that 2bind faced in the last years and how they overcame them. Don't miss out on this opportunity to learn from the best in the business! Tune in to our latest podcast episode and join the conversation on the future of biotech. Trust us; this episode is a must-listen for anyone in the biotech industry or anyone passionate about innovation and the future of medicine. It's packed with valuable insights and information you won't miss. 💡 LINKS TO MORE CONTENT. If you like the episode, become a subscriber and support the show: https://lsg2g.substack.com/subscribe Podcast Episodes: https://pod.link/1493847125 Check out our partners: https://linktr.ee/lsg2 Watch on Youtube Thomas Schubert Christian Soschner ⏰ Timestamps: 00:00) Introduction (02:00) Unveiling the mastermind behind 2bind, Dr. Thomas Schubert (04:05) Insider tips for starting your own biotech company (07:36) A glimpse into the future: 2022 for 2bind's CEO (10:40) Navigating the digital world: Pros and cons of technology in biotech (14:16) Overcoming obstacles: A look at 2bind's supply chain challenges (18:21) Game-changing developments in biophysics for 2022 (19:53) What's next for the industry? A preview of biophysics trends to come (23:19) Peeking into the crystal ball: 2bind's plans for 2023 (24:25) Mark your calendars: Upcoming conferences featuring 2bind in 2023 (30:49) Bold predictions for the biotech industry in 2023 (32:33) Addressing the challenges: How to improve drug discovery and development in 2023. Send us Fan Mail Support the show Join the Podcast Newsletter: Link Your Next Move: Link

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Spark 20: Alex Dang | Everyone Agrees? Think Again. How Venture Capitalists Decide

    Nov 1, 202629 minAudio

    Invest in the wrong startup and you lose one times your money. Miss the next Google and you lose ten thousand times. Most boards are built to avoid the first mistake. Venture capitalists play by different rules. They...

    Credit the people on this episode

  2. EP 185: Ivy Nguyen | IQ, EQ and the Execution Quotient Investors Fund

    Oct 18, 20261 hr 4 minAudio

    The trait a Silicon Valley AI investor rewards most in a management team has a name almost nobody uses: XQ. IQ brings the idea and EQ reads the people across the table. The execution quotient shows in something as small...

    Credit the people on this episode

  3. EP 184: Ivy Nguyen | 10,000 AI Pitches and the One Test That Matters

    Oct 15, 202659 minAudio

    In 2017 another investor told Ivy Nguyen that artificial intelligence was too small a niche to dedicate a fund to. More than ten thousand AI pitches later, every pitch deck says AI. Single funding rounds have grown...

    Credit the people on this episode

  4. EP 183: Marie Schroeder | Send the Rough Deck, Not the Perfect One

    Sep 27, 20262 hr 5 minAudio

    A seed investor at Novo Holdings would rather read your rough idea than your finished pitch deck. Most founders spend a year building the deck, forming the team and waiting until the story holds together. By the time it...

    Credit the people on this episode

  5. #182 - How to Lead When You Don't Know Where You Are Going: 4 Lessons from Ben Horowitz (Part 2 of 2)

    Sep 8, 202657 minAudio

    What does it mean when the most respected adviser in Silicon Valley tells you that you are the best chief executive he works with, while your company is heading straight into a wall? Bill Campbell said exactly that to...

    Credit the people on this episode